This video explores the evolving role of biomarkers in kidney cancer treatment, especially as more therapies become available for both metastatic and adjuvant settings. Key questions include which…
Medicosis Perfectionalis dives into renal cell carcinoma (RCC), a type of kidney cancer. The tutorial covers RCC’s origins in proximal renal tubular cells, the most common subtype (clear…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
According to patient recorded outcomes, the IN-Motion151 study met its co-primary endpoint of progression-free survival (PFS). Lead author Bernard Escudier, MD, of the Institut Gustave Roussy in Villejuif, France,…
In a poster presentation at ASCO 2018, authors shared data from a recent study which suggest that testing and modulating the composition of the gut microbiome can have…
In the largest prospective study of angiogenesis in metastatic renal cell carcinoma (mRCC) patients to date, an Italian study yielded data that suggests sorafenib had no meaningful impact…
